About: Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 March 1998

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 1998 (uk) article scientifique publié en 1998 (fr) im März 1998 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en marzu de 1998 (ast) scientific article published on 01 March 1998 (en)
publication date	wds:Q74329812-796119CE-82B8-44BB-9EE8-CB211D5375B6
publication date	1998-03-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q74329812-7331E1CF-ADF4-462B-A9B9-C673ACD278C6
language of work or name	English
author name string	wds:Q74329812-0CCD925B-5F48-4702-8D8F-A75C2CDD9B01 wds:Q74329812-11FFBD39-60D4-4F1D-A320-6B514DC4932D wds:Q74329812-2EEB1D68-B235-4D38-8B35-35D49A49D973 wds:Q74329812-4C976126-0E56-4981-857E-B8E65B96FA6E wds:Q74329812-512D5241-FCD4-4276-ADFC-8FE12154C26F wds:Q74329812-6C9F1313-DF6D-43AF-A398-6AA82AB7A3B9 wds:Q74329812-DE466A9A-64EE-4634-8D52-00D01BDAF22B wds:Q74329812-E6A8B646-8E5A-472A-8B2C-DE9A02BBEA6E wds:Q74329812-EF663376-8158-4B6F-9E50-5DED513C28EB wds:Q74329812-F48450E4-7C46-4809-A9D9-B9EAC8047701 wds:Q74329812-F8582F83-6BA2-49E8-8674-C5FBEBD25CCF
author name string	M Michael E A Eisenhauer M J Moore N Wainman L L Siu R Feld R A Goldberg J J Thiessen A M Oza J Manzo P S Firby
rdfs:label	Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks (en) Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks (nl)
skos:prefLabel	Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks (en) Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks (nl)
name	Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks (en) Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks (nl)
title	wds:Q74329812-08CAF50F-750A-4E79-977E-371FB9A75162
title	Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks (en)
page(s)	wds:Q74329812-04696CB8-73E1-454E-95AF-E255741C8786
page(s)	1122-1130
instance of	wds:Q74329812-C5F78B8A-3239-457A-81A5-E218F50862E7
instance of	scholarly article
PubMed ID	wds:Q74329812-16A9AB6F-15A9-4F13-8714-978F1A59D278
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9508199
PubMed ID	9508199
published in	wds:Q74329812-2C6DA586-37E8-4AF8-A401-8B6237F0FBB6
published in	Journal of Clinical Oncology
issue	wds:Q74329812-AB056CF9-58B6-41D2-9345-4BC57E9021A1
volume	wds:Q74329812-0D145EE2-486A-401A-BBA0-41BCA728A3B9
issue	3
volume	16
DOI	wds:Q74329812-32B64A9B-B162-4859-B6F8-45673F4AE906
DOI	http://dx.doi.org/10.1200/JCO.1998.16.3.1122
DOI	10.1200/JCO.1998.16.3.1122
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q74329812
is cites work of	Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia The camptothecins. Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer? Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer Oral topoisomerase 1 inhibitors in adult patients: present and future Clinical studies of camptothecin and derivatives
is cites work of	wds:Q47220295-2433A649-CA38-4E3D-A421-E80B4363C021 wds:Q43740784-3F7A4CCD-DF01-4B09-967C-D7FD4D8445FC wds:Q33180133-AEA7C01B-EE53-4A30-A7DA-7F546E151930 wds:Q46679638-8402FF87-950E-483B-92FB-CCDF47F8B7FF wds:Q35169644-E8FD5B97-21CB-4B71-ADB6-DCB7EB87AEF0 wds:Q77340375-9FDBB79C-9587-410D-84E7-18614B3AE8E2 wds:Q40804661-9778C955-7309-4AB5-A9C1-86291E31EC5A wds:Q33194418-0BD72DE9-1BA2-4A18-B539-B80951EF91CC wds:Q33339001-3510791D-EB69-4B6D-A16F-C1919920B172

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software